Early Detection and Management of Pulmonary Arterial Hypertension PDF Print E-mail
Wednesday, 06 March 2013 16:03
The long-term prognosis for patients with pulmonary arterial hypertension (PAH) remains poor, despite advances in treatment options that have been made in the past few decades. Recent evidence suggests that World Health Organization functional class I or II patients have significantly better long-term survival rates than patients in higher functional classes, thus providing a rationale for earlier diagnosis and treatment of PAH. However, early diagnosis is challenging and there is frequently a delay between symptom onset and diagnosis.

Screening programmes play an important role in PAH detection and expert opinion favours echocardiographic screening of asymptomatic patients who may be predisposed to the development of PAH (i.e. those with systemic sclerosis or sickle cell disease), although current guidelines only recommend annual echocardiographic screening in symptomatic patients. This article reviews the currently available screening programmes, including their limitations, and describes alternative screening approaches that may identify more effectively those patients who require right heart catheterisation for a definitive PAH diagnosis.

To read the full article, click on and download from the link provided below.


 
More articles :

» Actelion Pharmaceuticals announces availability of PAH Mobile Reference Guide

Actelion Pharmaceuticals US, Inc. is announcing the availability of the Pulmonary Arterial Hypertension (PAH) Mobile Reference Guide, the first multimedia smart phone application that provides information on PAH disease, pathology, diagnosis, and...

» Th22 Cells As Milestone Of Immunological Research

The newly discovered Th22 cells are a previously unknown subset of . T helper cells are white blood cells that help activate other immune cells when the body is infected by viruses or bacteria. At the same time they help the body to tolerate own...

» Placebo-controlled Study of Methotrexate in Juvenile Localised Scleroderma

According to the results of this placebo-controlled study, is an effective treatment for juvenile localised scleroderma (JLS). The authors note that JLS is a chronic progressive fibrotic process of the skin causing permanent disability and...

» Mixed Connective Tissue Disease May Represent Subset of Systemic Scleroderma

Many patients with (MCTD) may represent a subset of Systemic , rather than a disease involving overlapping connective tissue disorders as is commonly believed, or a subset of Lupus as some have suggested over the years, Dr. Virginia Steen said at...

» Living With A Chronic Illness

Properly diagnosing a chronic illness can take anywhere from two to three years. Many of you wait even longer. In the meantime, while the doctors scratch their heads, we’re expected to be happy we’re alive. And that’s if they don’t write us...

» Therapies for Scleroderma-related Pulmonary Arterial Hypertension

Paul M. HassounPosted: 08/20/2009; Expert Rev Resp Med. 2009;3(2):187-196. © 2009 Expert Reviews Ltd.Pulmonary arterial hypertension (PAH), a common complication of systemic sclerosis, carries a very severe prognosis and is one of the leading...